18F-αvβ6-BP for Cancer
Trial Summary
What is the purpose of this trial?
This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.
Research Team
Julie Sutcliffe
Principal Investigator
University of California, Davis
Eligibility Criteria
This trial is for people with primary or metastatic breast, colorectal, lung, or pancreatic cancer who can stay still for PET scans and have a good performance status. It's not for those with severe kidney/liver issues, very short life expectancy, pregnant/breastfeeding women, recent investigational drug use, or inability to undergo PET/CT scans.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 18F-alphavbeta6-BP intravenously and undergo 4 PET scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- 18F-αvβ6-BP
Find a Clinic Near You
Who Is Running the Clinical Trial?
Julie L. Sutcliffe, Ph.D
Lead Sponsor
National Cancer Institute (NCI)
Collaborator